Lupus Pipeline Could See Momentum Following Two New US Approvals

Lupus Therapeutics Sees Improved Outlook For Challenging Area Of Drug Development

Albert Roy, executive director of the clinical research arm of the Lupus Research Alliance, talked to Scrip about the outlook for lupus drug development.

Purple ribbon — Lupus Therapeutics hopes to see advances in drug development for SLE And LN • Source: Shutterstock

Two recent US Food and Drug Administration approvals of lupus nephritis treatments are a positive signal for future drug development in this notoriously challenging disease, Lupus Therapeutics executive director Albert Roy said in a recent interview with Scrip.

Roy has a broad perspective of the field of research

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

30 Apr 2025

• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

29 Apr 2025

• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.